No current policy or practice designed to improve care for dying Americans is backed by a fraction of the evidence that the FDA would require to approve even a relatively innocuous drug. Achieving evidence-based end-of-life care will require several key developments.
No takes yet. Share an insight, caveat, or question.
Scott D. Halpern (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: